Form 8-K - Current report:
SEC Accession No. 0000950170-25-072046
Filing Date
2025-05-15
Accepted
2025-05-15 08:58:09
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20250515.htm   iXBRL 8-K 53512
2 EX-99.1 aktx-ex99_1.htm EX-99.1 38361
3 GRAPHIC img218604663_0.jpg GRAPHIC 67599
4 GRAPHIC img218604663_1.jpg GRAPHIC 364446
5 GRAPHIC img218604663_2.jpg GRAPHIC 255066
  Complete submission text file 0000950170-25-072046.txt   1268268

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20250515.xsd EX-101.SCH 97669
17 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20250515_htm.xml XML 6056
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 25949058
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)